阿尔茨海默病生物标志物可能有助于预测最初恢复正常的 MCI 病例的预后。
Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal.
机构信息
From Alzheimer Center Amsterdam, Department of Neurology (L.V., A.J.L.v.P., P.S., P.J.V., B.M.T.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC; and Department of Psychiatry and Neuropsychology (P.J.V.), School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, the Netherlands.
出版信息
Neurology. 2019 Jun 4;92(23):e2699-e2705. doi: 10.1212/WNL.0000000000007609. Epub 2019 May 8.
OBJECTIVE
To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC).
METHODS
We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative. Common clinical markers, Alzheimer disease (AD) biomarkers, and neurodegeneration imaging markers were used to compare MCI reverters based on subsequent clinical outcome (i.e., subsequent decline or stable reversion). For independent comparison, findings of the clinical Amsterdam Dementia Cohort are presented.
RESULTS
Seventy-seven (10%) out of 757 individuals with MCI reverted to NC and 61 of these individuals had follow-up data available. After 3.2 ± 2.2 years, 16 (24%) progressed to MCI, and 3 (5%) to dementia. Those who declined were older and had a higher amyloid PET burden and higher CSF tau levels.
CONCLUSION
In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline. AD biomarkers may aid in the prognosis of reverting MCI.
目的
确定认知正常（NC）的轻度认知障碍（MCI）患者恢复认知正常后的预后相关因素。
方法
我们从阿尔茨海默病神经影像学倡议（Alzheimer's Disease Neuroimaging Initiative）中选择了在随访中恢复为 NC 的 MCI 患者，并在恢复后进行随访。采用常见的临床标志物、阿尔茨海默病（AD）生物标志物和神经退行性变影像学标志物，根据随后的临床结局（即随后的衰退或稳定恢复）对 MCI 恢复者进行比较。为了进行独立比较，还呈现了阿姆斯特丹痴呆队列研究（Amsterdam Dementia Cohort）的研究结果。
结果
在 757 名 MCI 患者中，有 77 名（10%）恢复为 NC，其中 61 名有随访数据。3.2±2.2 年后，16 名（24%）进展为 MCI，3 名（5%）进展为痴呆。那些病情恶化的患者年龄更大，淀粉样蛋白 PET 负担更高，CSF 中的 tau 水平也更高。
结论
在 MCI 恢复者中，AD 病理的异常生物标志物与随后的衰退有关。AD 生物标志物可能有助于预测恢复的 MCI 的预后。
Zotero 插件